Bolourchian Noushin, Bahjat Maryam
Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Turk J Pharm Sci. 2019 Sep;16(3):340-347. doi: 10.4274/tjps.galenos.2018.24861. Epub 2019 Jul 10.
The aim of this investigation was to develop an extended release formulation of diltiazem hydrochloride (DL) for once- and twice-daily administration, based on Eudragit (Eud) RL and RS microspheres using emulsion solvent evaporation.
Formulations with different drug-polymer concentrations were produced and characterized in terms of yield, encapsulation efficiency (EE), particle size, and surface morphology. The drug release and thermal behavior of the microspheres were also investigated. Selected microspheres were then coated with Eud RS by continuous solvent evaporation, in order to modify the microspheres' properties and burst release.
According to the results, the EE was in the range of 56%-93% for uncoated microspheres. The mean particle size of microspheres was different from 470 to above 1000 μm, based on various formulation variables. No difference was observed between the mean size of particles prepared with Eud RL and Eud RS. Microspheres showed sustained release behavior, which was affected by the drug:polymer ratio as well as particle size. Coating the microspheres not only improved the EE values (82%-92%) but also reduced the mean dissolution rate as well as the burst release.
Microspheres prepared with DL:Eud RL ratios of 1:3 and 1:4 showed release profiles in accordance with the USP criteria for a DL extended release product for dosing every 12 and 24 h, respectively.
本研究旨在基于聚醋酸乙烯邻苯二甲酸酯(Eudragit,Eud)RL和RS微球,采用乳液溶剂蒸发法开发一种用于每日一次和每日两次给药的盐酸地尔硫䓬(DL)缓释制剂。
制备了不同药物 - 聚合物浓度的制剂,并对其产率、包封率(EE)、粒径和表面形态进行了表征。还研究了微球的药物释放和热行为。然后通过连续溶剂蒸发用Eud RS对选定的微球进行包衣,以改变微球的性质和突释情况。
结果显示,未包衣微球的EE在56% - 93%范围内。基于各种制剂变量,微球的平均粒径在470至1000μm以上有所不同。用Eud RL和Eud RS制备的颗粒平均尺寸之间未观察到差异。微球表现出缓释行为,这受到药物与聚合物比例以及粒径的影响。对微球进行包衣不仅提高了EE值(82% - 92%),还降低了平均溶解速率以及突释情况。
以DL与Eud RL比例为1:3和1:4制备的微球,其释放曲线分别符合美国药典(USP)关于DL缓释产品每12小时和24小时给药一次的标准。